IP : India's Compulsory Licensing Case

A tussle over a Bayer drug patent could set a precedent in developing countries.

June 5, 2012

A March decision from the Indian Patent Office has caught the attention of pharmaceutical patent holders around the world. For the first time in India, a generic drug manufacturer has been granted a compulsory license to manufacture and sell a generic version of a patented drug. Though Bayer Corp., the drug's manufacturer, has appealed, the decision may provide a framework that supports future efforts at compulsory licensing in India and, perhaps, beyond.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.

Disclaimer

Related Publications

December 8, 2022
Lessons From MMAS Research About Dispositive Pitfalls in Copyright Litigation
David Martinez, Austin Miller - Los Angeles & San Francisco Daily Journal
November 19, 2022
How to Use the USPTO Patent Public Search Tool
Miles Finn, Rajin Olson, Kelson Bain, and Ian LaForge - IPWatchdog
October 2022
In No Uncertain Terms
Bryan Mechell - The Robins Kaplan Quarterly
September 13, 2022
Patent Value: Scoring Patents Using Characteristics Of Patents In Litigation
Christopher K. Larus, Miles A. Finn, Congnan Zhan, Joseph (Yu) Chen, and Shelley Gilliss - les Nouvelles
September 2, 2022
Trade Dress Through a Trial Lens: Six Strategy Tips For Litigants
Christopher Larus, William Manske - Managing IP
Back to Top